Anti-FOXC1抗体- ChIP Grade (ab5079)

概述

  • 产品名称
    Anti-FOXC1抗体- ChIP Grade
    参阅全部 FOXC1 一抗
  • 描述
    山羊多克隆抗体to FOXC1 - ChIP Grade
  • 宿主
    Goat
  • 经测试应用
    适用于: ChIP, WB, IHC-Pmore details
  • 种属反应性
    与反应: Mouse, Human, Zebrafish
    预测可用于: Xenopus laevis, Catfish
  • 免疫原

    Synthetic peptide:

    RTSGAFVYDCSKF

    , corresponding to amino acids 541-553 of Human FOXC 1.

性能

应用

Our Abpromise guarantee covers the use of ab5079 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

应用 Ab评论 说明
ChIP Use at an assay dependent dilution. PubMed: 17000708
WB Use a concentration of 0.5 - 1 µg/ml. Predicted molecular weight: 57 kDa.Can be blocked with Human FOXC1 peptide (ab23069).
IHC-P Use a concentration of 4 - 6 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

靶标

  • 功能
    Binding of FREAC-3 and FREAC-4 to their cognate sites results in bending of the DNA at an angle of 80-90 degrees.
  • 组织特异性
    Expressed in all tissues and cell lines examined.
  • 疾病相关
    Defects in FOXC1 are the cause of Axenfeld-Rieger syndrome type 3 (RIEG3) [MIM:602482]; also known as Axenfeld-Rieger syndrome (ARS) or Axenfeld syndrome or Axenfeld anomaly. It is characterized by posterior corneal embryotoxon, prominent Schwalbe line and iris adhesion to the Schwalbe line. Other features may be hypertelorism (wide spacing of the eyes), hypoplasia of the malar bones, congenital absence of some teeth and mental retardation. When associated with tooth anomalies, the disorder is known as Rieger syndrome. Glaucoma is a progressive blinding condition that occurs in approximately half of patients with Axenfeld-Rieger malformations.
    Defects in FOXC1 are the cause of iridogoniodysgenesis anomaly (IGDA) [MIM:601631]. IGDA is an autosomal dominant phenotype characterized by iris hypoplasia, goniodysgenesis, and juvenile glaucoma.
    Defects in FOXC1 are a cause of Peters anomaly (PAN) [MIM:604229]. Peters anomaly consists of a central corneal leukoma, absence of the posterior corneal stroma and Descemet membrane, and a variable degree of iris and lenticular attachments to the central aspect of the posterior cornea.
  • 序列相似性
    Contains 1 fork-head DNA-binding domain.
  • 细胞定位
    Nucleus.
  • Information by UniProt
  • 数据库链接
  • 别名
    • ARA antibody
    • FKH L7 antibody
    • FKHL 7 antibody
    • FKHL7 antibody
    • Forkhead (Drosophila) like 7 antibody
    • Forkhead box C1 antibody
    • Forkhead box protein C1 antibody
    • Forkhead drosophila homolog like 7 antibody
    • Forkhead like 7 antibody
    • Forkhead related activator 3 antibody
    • Forkhead related protein FKHL7 antibody
    • Forkhead related transcription factor 3 antibody
    • Forkhead-related protein FKHL7 antibody
    • Forkhead-related transcription factor 3 antibody
    • FOX C1 antibody
    • FOXC 1 antibody
    • Foxc1 antibody
    • FOXC1_HUMAN antibody
    • FREAC 3 antibody
    • FREAC-3 antibody
    • FREAC3 antibody
    • IGDA antibody
    • IHG 1 antibody
    • IHG1 antibody
    • IRID 1 antibody
    • IRID1 antibody
    • Iridogoniodysgenesis type 1 antibody
    • Myeloid factor delta antibody
    see all

图片

  • Lane 1 : Anti-FOXC1 antibody - ChIP Grade (ab5079) at 0.5 µg/ml
    Lane 2 : Anti-FOXC1 antibody - ChIP Grade (ab5079) at 0.5 mg/ml
    Lane 3 : anti- DYKDDDDK Tag at 1/3000 dilution

    Lanes 1 & 3 : HEK293 lysate (in RIPA buffer)
    Lane 2 : Mock-transfected HEK293 lysate (in RIPA buffer)

    Lysates/proteins at 10 µg per lane.

    Predicted band size: 57 kDa
    Observed band size: 75 kDa (why is the actual band size different from the predicted?)



    Primary incubations were for 1 hour.

    Detected by chemiluminescence.

  • Mouse tissue sections (periocular mesenchyme, cornea) were incubated with ab5079, anti-FOXC1 antibody. Paraformaldehyde was used for fixation, and a heat mediated antigen retrieval step was used. The antibody was incubated for 8 hours at a dilution of 1/200.
  • ab5079 at 3ug/ml staining FOXC1 in human kidney tissue section by Immunohistochemistry (Formalin/PFA fixed paraffin-embedded sections). Tissue underwent antigen retrieval in microwave with Tris/EDTA buffer (pH 9.0). The HRP-staining procedure was used for detection.

  • Immunohistochemical analysis of formalin-fixed, paraffin-embedded Human kidney tissue, staining FOXC1 with ab5079 at 4 µg/ml. Antigen retrieval was performed by heat mediation in a citrate buffer (pH 6).

文献

This product has been referenced in:
  • Wu J  et al. CircIRAK3 sponges miR-3607 to facilitate breast cancer metastasis. Cancer Lett 430:179-192 (2018). WB . Read more (PubMed: 29803789) »
  • Zhu X  et al. FoxC1 promotes epithelial-mesenchymal transition through PBX1 dependent transactivation of ZEB2 in esophageal cancer. Am J Cancer Res 7:1642-1653 (2017). Read more (PubMed: 28861321) »

See all 19 Publications for this product

客户评价及客户问答

Filter by Application

Filter by Species

Filter by Ratings

Application
Immunoprecipitation
Sample
Human Cell lysate - nuclear (MV411 transfected with FOXC1 plasmid)
Total protein in input
20 cells
Immuno-precipitation step
Protein G
Specification
MV411 transfected with FOXC1 plasmid
Username

Fabrizio Simeoni

Verified customer

提交于 Mar 28 2017

Abcam guarantees this product to work in the species/application used in this Abreview.
Application
Western blot
Sample
Human Cell lysate - whole cell (T47D)
Loading amount
100 µg
Specification
T47D
Treatment
10 nM si RNA 48 h
Blocking step
Serum, BSA, milk sequential incubations as blocking agent for 3 hour(s) and 0 minute(s) · Concentration: 5%
Username

Dr. F Stanley

Verified customer

提交于 Mar 05 2007

Abcam guarantees this product to work in the species/application used in this Abreview.
Application
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Sample
Mouse Tissue sections (periocular mesenchyme, cornea)
Specification
periocular mesenchyme, cornea
Fixative
Paraformaldehyde
Antigen retrieval step
Heat mediated
Blocking step
Other as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 1%
Username

Ms. Amanda Evans-Zacharias

Verified customer

提交于 Feb 08 2006

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

注册